Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Net Income: 2019-2024

Historic Net Income for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Dec 2024 value amounting to -$259.6 million.

  • Maravai Lifesciences Holdings' Net Income rose 73.87% to -$45.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$213.8 million, marking a year-over-year increase of 33.91%. This contributed to the annual value of -$259.6 million for FY2024, which is 87.62% down from last year.
  • Latest data reveals that Maravai Lifesciences Holdings reported Net Income of -$259.6 million as of FY2024, which was down 87.62% from -$138.4 million recorded in FY2023.
  • Over the past 5 years, Maravai Lifesciences Holdings' Net Income peaked at $490.7 million during FY2022, and registered a low of -$259.6 million during FY2024.
  • Moreover, its 3-year median value for Net Income was -$138.4 million (2023), whereas its average is $30.9 million.
  • As far as peak fluctuations go, Maravai Lifesciences Holdings' Net Income surged by 1,615.40% in 2020, and later tumbled by 128.20% in 2023.
  • Maravai Lifesciences Holdings' Net Income (Yearly) stood at $78.8 million in 2020, then surged by 495.37% to $469.2 million in 2021, then grew by 4.56% to $490.7 million in 2022, then slumped by 128.20% to -$138.4 million in 2023, then crashed by 87.62% to -$259.6 million in 2024.